These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16704445)

  • 21. Marrow proliferation as a cause of hearing loss in beta-thalassaemia major.
    Thio D; Prasad V; Anslow P; Lennox P
    J Laryngol Otol; 2008 Nov; 122(11):1253-6. PubMed ID: 17931455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zinc deficiency aggravates abnormal glucose metabolism in thalassemia major patients.
    Dehshal MH; Hooghooghi AH; Kebryaeezadeh A; Kheirabadi M; Kazemi S; Nasseh A; Shariftabrizi A; Pasalar P
    Med Sci Monit; 2007 May; 13(5):CR235-9. PubMed ID: 17476196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Peculiarities of iron metabolism in patients with Beta - thalassemia at different periods after splenectomy].
    Kadimova E
    Georgian Med News; 2007 Nov; (152):35-7. PubMed ID: 18175831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI for the determination of pituitary iron overload in children and young adults with beta-thalassaemia major.
    Christoforidis A; Haritandi A; Perifanis V; Tsatra I; Athanassiou-Metaxa M; Dimitriadis AS
    Eur J Radiol; 2007 Apr; 62(1):138-42. PubMed ID: 17161570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary pseudomonas meningitis in an adult, splenectomized, multitransfused thalassaemia major patient.
    Ghosh K; Daar S; Hiwase D; Nursat N
    Haematologia (Budap); 2000; 30(1):69-72. PubMed ID: 10841329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compliance of deferoxamine injection in beta-thalassaemia major patients in Iran.
    Rashid M; Karimi M
    Transfus Med; 2012 Apr; 22(2):104-7. PubMed ID: 22212011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Central venous line thrombosis in children and young adults with thalassemia major.
    Finkelstein Y; Yaniv I; Berant M; Zilber R; Garty BZ; Epstein O; Lahav J; Tamary H
    Pediatr Hematol Oncol; 2004; 21(5):375-81. PubMed ID: 15205080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Celiac disease associated with major thalassemia. A case report].
    Mangiagli A; Campisi S
    Minerva Pediatr; 1996 Sep; 48(9):401-5. PubMed ID: 8992285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haemostatic disorders in nonsplenectomized and splenectomized thalassaemic children.
    Shebl SS; el-Sharkawy HM; el-Fadaly NH
    East Mediterr Health J; 1999 Nov; 5(6):1171-7. PubMed ID: 11924107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infections related to intrathecal baclofen therapy in children and adults: frequency and risk factors.
    Fjelstad AB; Hommelstad J; Sorteberg A
    J Neurosurg Pediatr; 2009 Nov; 4(5):487-93. PubMed ID: 19877786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis.
    Aydinok Y; Bayraktaroglu S; Yildiz D; Alper H
    J Pediatr Hematol Oncol; 2011 Jul; 33(5):374-8. PubMed ID: 21364469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocrine complications in patients with Thalassaemia Major.
    Toumba M; Sergis A; Kanaris C; Skordis N
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes mellitus in children suffering from beta-thalassaemia.
    el-Hazmi MA; al-Swailem A; al-Fawaz I; Warsey AS; al-Swailem A
    J Trop Pediatr; 1994 Oct; 40(5):261-6. PubMed ID: 7807619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P; Grady RW; Dragsten P; Vichinsky E; Giardina P; Madden J; Jeng M; Miller B; Hanson G; Hedlund B
    Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of infection and death among post-splenectomy patients.
    Bisharat N; Omari H; Lavi I; Raz R
    J Infect; 2001 Oct; 43(3):182-6. PubMed ID: 11798256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infection outcomes in splenectomized patients with hemoglobinopathies in Australia.
    Yapp AR; Lindeman R; Gilroy N; Gao Z; Macintyre CR
    Int J Infect Dis; 2009 Nov; 13(6):696-700. PubMed ID: 19136288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and economic burden of infused iron chelation therapy in the United States.
    Payne KA; Desrosiers MP; Caro JJ; Baladi JF; Lordan N; Proskorovsky I; Ishak K; Rofail D
    Transfusion; 2007 Oct; 47(10):1820-9. PubMed ID: 17880607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homozygous beta-thalassaemia: a review of patients who had splenectomy at the Royal Alexandra Hospital for Children, Sydney.
    Hoe TS; Lammi A; Webster B
    Singapore Med J; 1994 Feb; 35(1):59-61. PubMed ID: 8009282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Retinal pigment epithelium--desferal].
    Roulez F
    Bull Soc Belge Ophtalmol; 2007; (304):59-66. PubMed ID: 17718228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.